Details of the Drug

General Information of Drug (ID: DMB0FWL)

• Drug Name: Dihydrocodeine
• Synonyms: Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine

Indication

Disease Entry	ICD 11	Status	REF
Cancer related pain	MG30	Phase 4	[1], [2]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 301.4
  Topological Polar Surface Area (xlogp); 2.2
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Clearance: The drug present in the plasma can be removed from the body at the rate of 4.21 mL/min/kg [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 4 hours [3]
  Metabolism: The drug is metabolized via the liver [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.07 L/kg [3]
• Chemical Identifiers:
  Formula: C18H23NO3
  IUPAC Name: (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
  Canonical SMILES: CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O
  InChI: InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
  InChIKey: RBOXVHNMENFORY-DNJOTXNNSA-N
• Cross-matching ID:
  PubChem CID: 5284543
  ChEBI ID: CHEBI:135276
  CAS Number: 125-28-0
  DrugBank ID: DB01551
  TTD ID: D0T6RC
  INTEDE ID: DR0500

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor (OPR)	TTN4QDT	NOUNIPROTAC	Modulator	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[7]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[8]
UDP-glucuronosyltransferase 2B4 (UGT2B4)	DENUPDX	UD2B4_HUMAN	Substrate	[8]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dihydrocodeine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Levomilnacipran	DMV26S8	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Levomilnacipran.	Chronic pain [MG30]	[47]

Coadministration of a Drug Treating the Disease Different from Dihydrocodeine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Dihydrocodeine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[48]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Oliceridine.	Acute pain [MG31]	[49]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Dihydrocodeine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[50]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Cariprazine.	Bipolar disorder [6A60]	[49]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Dihydrocodeine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[51]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Dihydrocodeine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[52]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Dihydrocodeine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[53]
Vilazodone	DM4LECQ	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Vilazodone.	Depression [6A70-6A7Z]	[47]
Vortioxetine	DM6F1PU	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Vortioxetine.	Depression [6A70-6A7Z]	[54]
Milnacipran	DMBFE74	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Milnacipran.	Depression [6A70-6A7Z]	[47]
Desvenlafaxine	DMHD4PE	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and Desvenlafaxine.	Depression [6A70-6A7Z]	[47]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Dihydrocodeine and OPC-34712.	Depression [6A70-6A7Z]	[49]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Esketamine.	Depression [6A70-6A7Z]	[55]
Mepenzolate	DM8YU2F	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Mepenzolate.	Digestive system disease [DE2Z]	[56]
5-hydroxy-L-tryptophan	DMDWZGJ	Moderate	Additive serotonergic effects by the combination of Dihydrocodeine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[47]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Dihydrocodeine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[57]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Dihydrocodeine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Dihydrocodeine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[58]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Dihydrocodeine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[59]
Solifenacin	DMG592Q	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Solifenacin.	Functional bladder disorder [GC50]	[56]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Dihydrocodeine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[60]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Dihydrocodeine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[61]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Dihydrocodeine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Belladonna	DM2RBWK	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[56]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Dihydrocodeine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[62]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Suvorexant.	Insomnia [7A00-7A0Z]	[49]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Tasimelteon.	Insomnia [7A00-7A0Z]	[49]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Paraldehyde.	Insomnia [7A00-7A0Z]	[49]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Dihydrocodeine and ITI-007.	Insomnia [7A00-7A0Z]	[49]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Quazepam.	Insomnia [7A00-7A0Z]	[49]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Dihydrocodeine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[63]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[49]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Dihydrocodeine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[48]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Dihydrocodeine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[64]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Dihydrocodeine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[48]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Dihydrocodeine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[58]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Dihydrocodeine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[65]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Dihydrocodeine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[66]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Dihydrocodeine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[67]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Dihydrocodeine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[58]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[64]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Lasmiditan.	Migraine [8A80]	[55]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Dihydrocodeine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[68]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Flibanserin.	Mood disorder [6A60-6E23]	[55]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Dihydrocodeine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[69]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Dihydrocodeine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[70]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Dihydrocodeine due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[71]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Dihydrocodeine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[72]
Pimavanserin	DMR7IVC	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Pimavanserin.	Parkinsonism [8A00]	[49]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dihydrocodeine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[73]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Dihydrocodeine and Methylscopolamine.	Peptic ulcer [DA61]	[74]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Dihydrocodeine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[75]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Dihydrocodeine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[76]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Dihydrocodeine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[58]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Iloperidone.	Schizophrenia [6A20]	[49]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Molindone.	Schizophrenia [6A20]	[49]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Thiothixene.	Schizophrenia [6A20]	[49]
Asenapine	DMSQZE2	Major	Additive CNS depression effects by the combination of Dihydrocodeine and Asenapine.	Schizophrenia [6A20]	[49]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Dihydrocodeine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[69]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Dihydrocodeine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[58]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Dihydrocodeine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[71]
Armodafinil	DMGB035	Minor	Increased metabolism of Dihydrocodeine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[77]
LEE011	DMMX75K	Moderate	Decreased metabolism of Dihydrocodeine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[78]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Dihydrocodeine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[48]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Dihydrocodeine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[79]
Brilinta	DMBR01X	Moderate	Altered absorption of Dihydrocodeine due to GI dynamics variation caused by Brilinta.	Thrombosis [DB61-GB90]	[71]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7594).
• [2] ClinicalTrials.gov (NCT00547885) Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain. U.S. National Institutes of Health.
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [5] Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
• [6] Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22.
• [7] The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106.
• [8] Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
• [9] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [10] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [11] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [12] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [15] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [16] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [17] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [18] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [19] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [20] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [21] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [22] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [23] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [24] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [25] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [26] Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
• [27] Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
• [28] Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
• [29] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [30] Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
• [31] Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
• [32] Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
• [33] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [34] Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
• [35] Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol. 2012 May;73(5):786-94.
• [36] Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
• [37] Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
• [38] The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
• [40] Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
• [41] mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
• [42] An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
• [43] Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
• [44] Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
• [45] Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
• [46] Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
• [47] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [48] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [49] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [50] Product Information. Ambien (zolpidem). sanofi-aventis, Bridgewater, NJ.
• [51] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [52] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83. [PMID: 9834039]
• [53] Product Information. Prevymis (letermovir). Merck &amp Company Inc, Whitehouse Station, NJ.
• [54] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5. [PMID: 18171260]
• [55] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [56] Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
• [57] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [58] Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
• [59] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
• [60] Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
• [61] Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
• [62] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [63] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [64] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [65] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [66] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10. [PMID: 9723817]
• [67] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [68] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [69] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
• [70] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [71] Cerner Multum, Inc. "Australian Product Information.".
• [72] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [73] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [74] Product Information. Lortab (acetaminophen-hydrocodone). Akorn Inc, Buffalo Grove, IL.
• [75] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [76] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [77] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [78] Kane GC, Lipsky JJ "Drug-grapefruit juice interactions." Mayo Clin Proc 75 (2000): 933-42. [PMID: 10994829]
• [79] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.